Steatosis and NASH in type 2 diabetes

被引：44
|
作者：
Hu, Mengyue [1 ,2 ]
Phan, Franck [1 ,2 ]
Bourron, Olivier [1 ,2 ,3 ,4 ]
Ferre, Pascal [1 ,2 ]
Foufelle, Fabienne [1 ,2 ,3 ,4 ]
机构：
[1] Sorbonne Univ, INSERM UMRS 1138, Ctr Rech Cordeliers, F-75006 Paris, France
[2] Univ Paris Diderot, Ctr Rech Cordeliers, Sorbonne Paris Cite, Univ Paris Descartes, F-75006 Paris, France
[3] AP HP, Dept Endocrinol Nutr & Diabet, Paris, France
[4] Hop La Pitie Salpetriere, AP HP, ICAN, Paris, France
来源：
BIOCHIMIE | 2017年 / 143卷
关键词：
Steatosis; NASH; Insulin resistance; Inflammation; Lipotoxicity; Type; 2; diabetes; FATTY LIVER-DISEASE; DE-NOVO LIPOGENESIS; NF-KAPPA-B; INSULIN-RESISTANCE; HEPATIC STEATOSIS; NONALCOHOLIC STEATOHEPATITIS; IKK-BETA; RISK; OBESITY; MICE;
D O I：
10.1016/j.biochi.2017.10.019
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Non Alcoholic Fatty Liver Disease (NAFLD) is currently the most common chronic liver disease in the world, encompassing various conditions ranging from simple steatosis, steatohepatitis, to fibrosis and cirrhosis. The association between NAFLD and Type 2 Diabetes (T2D) is strong and complex, given that the prevalence of NAFLD is particularly high in individuals with Type 2 Diabetes. In fact, insulin resistance occurring in this metabolic disease can promote NAFLD development, and vice versa, NAFLD can enhance insulin resistance. In this review, we focus on the mechanisms linking NAFLD and T2D, including fatty acid accumulation, inflammation, oxidative stress etc. We also discuss about situations showing a dissociation between steatosis and insulin resistance, in order to provide new insights for NAFLD therapeutic targets. (C) 2017 Elsevier B.V. and Societe Francaise de Biochimie et Biologie Moleculaire (SFBBM). All rights reserved.
引用
收藏
页码：37 / 41
页数：5
相关论文
共 50 条
  • [21] Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation
    Peverill, William
    Powell, Lawrie W.
    Skoien, Richard
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2014, 15 (05): : 8591 - 8638
  • [22] The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
    Younossi, Zobair M.
    Golabi, Pegah
    de Avila, Leyla
    Paik, James Minhui
    Srishord, Manirath
    Fukui, Natsu
    Qiu, Ying
    Burns, Leah
    Afendy, Arian
    Nader, Fatema
    JOURNAL OF HEPATOLOGY, 2019, 71 (04) : 793 - 801
  • [23] Bazedoxifene and conjugated estrogen prevent diet-induced obesity, hepatic steatosis, and type 2 diabetes in mice without impacting the reproductive tract
    Barrera, Jose
    Chambliss, Ken L.
    Ahmed, Mohamed
    Tanigaki, Keiji
    Thompson, Bonne
    McDonald, Jeffrey G.
    Mineo, Chieko
    Shaul, Philip W.
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2014, 307 (03): : E345 - E354
  • [24] Retinoic acid receptor β2 agonists restore glycaemic control in diabetes and reduce steatosis
    Trasino, S. E.
    Tang, X-H.
    Jessurun, J.
    Gudas, L. J.
    DIABETES OBESITY & METABOLISM, 2016, 18 (02): : 142 - 151
  • [25] Up-regulation of PPARγ, heat shock protein-27 and -72 by naringin attenuates insulin resistance, β-cell dysfunction, hepatic steatosis and kidney damage in a rat model of type 2 diabetes
    Sharma, Ashok Kumar
    Bharti, Saurabh
    Ojha, Shreesh
    Bhatia, Jagriti
    Kumar, Narender
    Ray, Ruma
    Kumari, Santosh
    Arya, Dharamvir Singh
    BRITISH JOURNAL OF NUTRITION, 2011, 106 (11) : 1713 - 1723
  • [26] Decreased expression of the NLRP6 inflammasome is associated with increased intestinal permeability and inflammation in obesity with type 2 diabetes
    Fruehbeck, Gema
    Gomez-Ambrosi, Javier
    Ramirez, Beatriz
    Becerril, Sara
    Rodriguez, Amaia
    Mentxaka, Amaia
    Valenti, Victor
    Moncada, Rafael
    Reina, Gabriel
    Baixauli, Jorge
    Casado, Marcos
    Silva, Camilo
    Escalada, Javier
    Catalan, Victoria
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2024, 81 (01)
  • [27] Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)
    Lavynenko, Olga
    Abdul-Ghani, Muhammad
    Alatrach, Mariam
    Puckett, Curtiss
    Adams, John
    Abdelgani, Siham
    Alkhouri, Naim
    Triplitt, Curtis
    Clarke, Geoffrey D.
    Vasquez, Juan A.
    Li, Jinqi
    Cersosimo, Eugenio
    Gastaldelli, Amalia
    DeFronzo, Ralph A.
    DIABETES OBESITY & METABOLISM, 2022, 24 (05): : 899 - 907
  • [28] MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis
    Segura-Azuara, Nancy de los angeles
    Varela-Chinchilla, Carlos Daniel
    Trinidad-Calderon, Plinio A.
    FRONTIERS IN MEDICINE, 2022, 8
  • [29] Metabolic parameters associated with arterial stiffness in older adults with Type 2 diabetes: the Edinburgh Type 2 Diabetes Study
    Teoh, Wei Leng
    Price, Jackie F.
    Williamson, Rachel M.
    Payne, Rupert A.
    Van Look, Liesbeth A. F.
    Reynolds, Rebecca M.
    Frier, Brian M.
    Wilkinson, Ian B.
    Webb, David J.
    Strachan, Mark W. J.
    JOURNAL OF HYPERTENSION, 2013, 31 (05) : 1010 - 1017
  • [30] Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes
    Qiang, Guifen
    Zhang, Li
    Yang, Xiuying
    Xuan, Qi
    Shi, Lili
    Zhang, Hengai
    Chen, Bainian
    Li, Xiaoxiu
    Zu, Mian
    Zhou, Dan
    Guo, Jing
    Yang, Haiguang
    Du, Guanhua
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2012, 685 (1-3) : 156 - 164
12345